Amarin's Wall Street Beating: Will It Recover?

Shares of Amarin were down 20% today, after the company surprised investors with its after-hours decision last night that it would be hiring a sales force of 200-300 representatives, ostensibly to market its new triglyceride-lowering drug, Vascepa, on its own. The company will be taking on $100 million in debt financing to pay for the new hirings.

Investors have been waiting with bated breath for the Food and Drug Administration to announce whether it will grant Vascepa new chemical entity, or NCE, status -- which would grant the drug five years of patent protection rather than three -- and would most likely be the catalyst for a buyout offer. The possible decision on NCE is still a week away, and although many analysts feel that an immediate buyout is a less likely scenario now, market pundits are still overall bullish on the stock, though many have lowered their projected price targets.

The biotech space can make or break investors overnight. Amarin has huge potential, but don't invest a dollar before reading everything you need to know about Amarin -- including an exclusive update on today's drop. You can start now with top analyst Max Macaluso's premium research report. Click here now to keep reading.

The article Amarin's Wall Street Beating: Will It Recover? originally appeared on

David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavidMax Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.